BIO-key International (NASDAQ:BKYI) Issues Earnings Results, Misses Expectations By $0.12 EPS

BIO-key International (NASDAQ:BKYI) announced its quarterly earnings data on Tuesday. The technology company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.12), FiscalAI reports. BIO-key International had a negative net margin of 70.23% and a negative return on equity of 73.33%. The business had revenue of $1.24 million during the quarter, compared to analysts’ expectations of $2.20 million.

BIO-key International Trading Up 4.3%

NASDAQ BKYI opened at $0.60 on Tuesday. BIO-key International has a 12 month low of $0.51 and a 12 month high of $1.97. The company has a 50-day moving average of $0.63 and a 200-day moving average of $0.70. The company has a market cap of $6.49 million, a P/E ratio of -0.58 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.26 and a quick ratio of 1.13.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BIO-key International stock. Geode Capital Management LLC grew its position in shares of BIO-key International Inc. (NASDAQ:BKYI) by 49.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,892 shares of the technology company’s stock after acquiring an additional 16,271 shares during the quarter. Geode Capital Management LLC owned about 0.45% of BIO-key International worth $26,000 at the end of the most recent quarter. 26.51% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on BKYI shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BIO-key International in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of BIO-key International to a “sell” rating in a research report on Saturday, January 3rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

BIO-key International Company Profile

BIO-key International, Inc is a developer and provider of fingerprint biometric identity and access management solutions, serving enterprise and government customers. The company’s core offerings include a range of fingerprint readers and authentication software designed to verify user identity across physical and digital environments. By leveraging proprietary template-on-card and template-on-device technologies, BIO-key seeks to enhance security and streamline user access without reliance on traditional passwords.

In addition to hardware sensors, BIO-key delivers software platforms that integrate with existing IT infrastructures such as Microsoft Active Directory and major workforce management systems.